Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Condition(s):Breast CancerLast Updated:January 29, 2016Completed
Hide Studies Not Open or Pending
Condition(s):Breast CancerLast Updated:January 29, 2016Completed
Condition(s):HER2-positive Breast Cancer; Breast CancerLast Updated:November 2, 2023Recruiting
Condition(s):Breast NeoplasmsLast Updated:July 15, 2020Completed
Condition(s):HER2-positive Metastatic Breast Cancer; First-line TreatmentLast Updated:February 26, 2024Recruiting
Condition(s):Breast CancerLast Updated:January 11, 2021Withdrawn
Condition(s):HER2 Positive Breast Cancer; Left Ventricular Function Systolic DysfunctionLast Updated:May 10, 2022Completed
Condition(s):HER2-positive Early Breast CancerLast Updated:April 1, 2021Recruiting
Condition(s):Breast NeoplasmsLast Updated:September 13, 2022Recruiting
Condition(s):HER2 Positive Early Breast CancerLast Updated:June 27, 2023Recruiting
Condition(s):Locally Advanced Breast CancerLast Updated:August 22, 2023Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.